⚕️ Medical Disclaimer
⚕️ Medical Disclaimer: Pipeline literacy only. Pemvidutide is not an FDA-approved obesity pen on the sources below. Not a reconstitution protocol.
What Pemvidutide Is
Pemvidutide (ALT-801) is Altimmune’s investigational balanced GLP-1 / glucagon receptor dual agonist. The public design story emphasizes roughly 1:1 GLP-1:glucagon activity — appetite and glycemic pathways via GLP-1, energy expenditure and hepatic fat oxidation via glucagon receptor agonism.
Identity leaf: /peptides/pemvidutide. It is not tirzepatide (GIP/GLP-1), not MariTide (GIPR antagonist / GLP-1 agonist), and not mazdutide (another GLP-1/glucagon dual agonist with a different sponsor and geography).
MOMENTUM Phase 2 — Numbers From Opened Sources
Altimmune’s November 30, 2023 topline release for the 48-week MOMENTUM Phase 2 obesity trial: 391 participants with overweight or obesity plus at least one comorbidity, without diabetes, randomized 1:1:1:1 to weekly pemvidutide 1.2 mg, 1.8 mg, 2.4 mg, or placebo with lifestyle intervention. The 2.4 mg arm used a short 4-week titration; lower doses were given without titration in that design.
At week 48, mean weight loss was 10.3%, 11.2%, and 15.6% on 1.2 / 1.8 / 2.4 mg versus 2.2% on placebo. Over 30% of participants on 2.4 mg achieved ≥20% weight loss in the company topline framing; over half achieved ≥15%. Lipid reductions and blood-pressure improvements were highlighted without clinically meaningful heart-rate increases in that release.
ADA abstract 262-OR (Diabetes 2024) reports the same 48-week mean losses (10.3 / 11.2 / 15.6% vs 2.2% placebo) and notes glycemic measures were largely stable. Treat company toplines and congress abstracts as sponsor-facing summaries until a full peer-reviewed methods paper is your citation of record.
Liver Fat Angle — Why Glucagon Matters
Glucagon receptors are enriched in hepatocytes. Dual GLP-1/glucagon agonists are often discussed for MASH / liver-fat programs as well as systemic obesity. Pemvidutide’s obesity MOMENTUM readout is not automatically a finished MASH label — keep indications separate until a specific trial endpoint says otherwise.
Lean-mass preservation claims circulate widely in marketing. Prefer body-composition endpoints published with methods over secondary slide claims. This essay will not invent a “75% fat / 25% lean” figure without an opened primary table in hand for that exact ratio.
How It Compares (Cross-Trial Caution)
Versus semaglutide STEP obesity programs: different populations, titration, and estimands — not a head-to-head. Versus tirzepatide: different second receptor (glucagon vs GIP). Versus mazdutide: same dual-agonist neighborhood, different sponsors, doses, and geographies (see GLORY-1 for mazdutide in Chinese adults).
Gray-market vials labeled pemvidutide are not MOMENTUM drug product. Skip DIY reconstitution folklore.
Status Check
As of the opened 2023–2024 Phase 2 materials, pemvidutide remained clinical-stage. Later Phase 3 timelines belong to company updates — verify before repeating “FDA filing 2027” style claims. Pipeline ≠ pen.